Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Tenapanor Hits Mark in Japan Hyperphosphatemia Study: Kyowa Kirin
Kyowa Kirin said on December 13 that its selective sodium-hydrogen exchanger 3 (NHE3) inhibitor tenapanor hit the primary endpoint in a Japan PIII trial for the treatment of hyperphosphatemia in patients on hemodialysis. The double-blind and placebo-controlled study assessed the…
To read the full story
Related Article
- Kyowa Kirin Files Hyperphosphatemia Drug in Japan
October 31, 2022
- Kyowa Kirin Commences Japan PIII of NHE3 Inhibitor for Hyperphosphatemia
April 14, 2021
- Kyowa Kirin’s Hyperphosphatemia Treatment Tenapanor Hits Primary Goal in Japan PII
June 10, 2020
- Kyowa Kirin Commences Japan PII Study of NHE3 Inhibitor for Hyperphosphatemia
February 7, 2019
- Kyowa Kirin Gains Rights to NHE3 Inhibitor in Japan
November 29, 2017
BUSINESS
- Takeda Says US Revamp “Not Simply Workforce Reduction” as 634 Roles Impacted
April 3, 2026
- New JCR President Confident in 100 Billion Yen Sales Target in 2030s
April 3, 2026
- Meiji Launches Rezurock in Thailand
April 3, 2026
- Mochida, LG Chem Ink Licensing Deal for Dienogest in South Korea, Thailand
April 3, 2026
- Lotte Invests in Rakuten Medical via Biopharma CVC
April 3, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…